Pfizer says pill to treat COVID-19 could be authorized by end of year or early 2022: 'It is a game changer'


Pfizer has announced that new data confirm its antiviral pill is effective at reducing the risk of hospitalization or death from COVID-19.
The company said Tuesday final trial results confirmed the antiviral pill reduced the risk of hospitalization or death for high-risk COVID-19 patients by 89 percent when given within three days of symptoms developing. This confirmed earlier data from a clinical trial. Pfizer executive Annaliesa Anderson previously told The New York Times that those results were "really beyond our wildest dreams."
Additionally, the company said Tuesday that the pill worked against the new Omicron variant of COVID-19 in lab studies, according to The New York Times.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
"This underscores the treatment candidate's potential to save the lives of patients around the world," Pfizer CEO Albert Bourla said.
Pfizer said this new data has been shared with the FDA as part of its Emergency Use Authorization submission, and Bourla told ABC News that the pill could be authorized in the United States by the end of the year or early 2022. "It is a game changer," Bourla also told ABC. "But at the same time, I want to emphasize that no one should use the existence of the pill as an excuse to avoid vaccination."
An FDA advisory panel previously recommended emergency authorization be granted to a COVID-19 pill from Merck. According to CNN, the FDA hasn't yet set a date for when its advisory committee will consider Pfizer's treatment.
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Brendan worked as a culture writer at The Week from 2018 to 2023, covering the entertainment industry, including film reviews, television recaps, awards season, the box office, major movie franchises and Hollywood gossip. He has written about film and television for outlets including Bloody Disgusting, Showbiz Cheat Sheet, Heavy and The Celebrity Cafe.
-
IAEA: Iran could enrich uranium 'within months'
Speed Read The chief United Nations nuclear inspector, Rafael Grossi, says Iran could be enriching uranium again soon
-
Sniper kills 2 Idaho firefighters in ambush
Speed Read A man started a wildfire, then fired a rifle at first responders when they arrived
-
Senate advances GOP bill that costs more, cuts more
Speed Read The bill would make giant cuts to Medicaid and food stamps, leaving 11.8 million fewer people with health coverage
-
Kennedy's vaccine panel signals skepticism, change
Speed Read RFK Jr.'s new vaccine advisory board intends to make changes to the decades-old US immunization system
-
Kennedy ousts entire CDC vaccine advisory panel
speed read Health Secretary RFK Jr. is a longtime anti-vaccine activist who has criticized the panel of experts
-
RFK Jr. scraps Covid shots for pregnant women, kids
Speed Read The Health Secretary announced a policy change without informing CDC officials
-
New FDA chiefs limit Covid-19 shots to elderly, sick
speed read The FDA set stricter approval standards for booster shots
-
US overdose deaths plunged 27% last year
speed read Drug overdose still 'remains the leading cause of death for Americans aged 18-44,' said the CDC
-
Trump seeks to cut drug prices via executive order
speed read The president's order tells pharmaceutical companies to lower prescription drug prices, but it will likely be thrown out by the courts
-
RFK Jr.: A new plan for sabotaging vaccines
Feature The Health Secretary announced changes to vaccine testing and asks Americans to 'do your own research'
-
RFK Jr. visits Texas as 2nd child dies from measles
Speed Read An outbreak of the vaccine-preventable disease continues to grow following a decade of no recorded US measles deaths